Back to top

Analyst Blog

Zoetis Inc.’s (ZTS - Analyst Report) third quarter 2013 earnings (excluding special items) of 34 cents per share fell short of the Zacks Consensus Estimate by a penny. Third quarter 2013 earnings were 10% above the year-ago figure. Higher revenues aided results in the reported quarter.

Revenues at Zoetis climbed to $1.1 billion in the third quarter of 2013 from $1 billion recorded a year ago. Foreign currency movements adversely impacted revenues during the quarter by 1%. Revenues edged past the Zacks Consensus Estimate of $1.07 billion. We note that Zoetis is the former Animal Health business of Pfizer Inc. (PFE - Analyst Report). Zoetis started trading on the New York Stock Exchange from Feb 1, 2013.

Zoetis boasts of a robust and diversified product portfolio. The product portfolio is divided into five categories – anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals for veterinarians and livestock producers.

Zoetis markets its offerings primarily across 8 species: cattle, swine, poultry, sheep and fish (livestock) and dogs, cats and horses (companion animals). In the third quarter of 2013, sales of livestock products accounted for 64% of total revenues. The balance came from the companion animal products.

Geographically, the company operates in four segments- the U.S, Europe/Africa/Middle East (EuAfME), Canada/Latin America (CLAR), and Asia/Pacific (APAC). Sales improved in the U.S. (10%), EuAfME (12%), CLAR (4%) and APAC (1%) markets. The growth rates are inclusive of foreign exchange impact.

2013 Outlook Modified

Zoetis updated its earlier provided guidance for 2013. The company now expects revenues in the range of $4.475-$4.525 billion (old guidance: $4.425 billion-$4.525 billion). The current Zacks Consensus Estimate stands at $4.48 billion. Zoetis narrowed its adjusted earnings guidance range for 2013 to $1.38-$1.42 per share from $1.36-$1.42 per share. The pre-earnings Zacks Consensus Estimate is $1.40 per share.

Zoetis currently carries a Zacks Rank #3 (Hold). Companies like Actelion Ltd. (ALIOF) and Isis Pharmaceuticals, Inc. (ISIS - Analyst Report) appear to be well placed with a Zacks Rank #1 (Strong Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
ALASKA AIR… ALK 96.79 +2.26%
PILGRIMS PR… PPC 29.50 +1.90%
SASOL LTD -… SSL 58.83 +1.78%
NSK LTD -UN… NPSKY 26.70 +1.52%
CTPARTNERS… CTP 10.99 +1.29%